Media Coverage

Prescription and illicit drug testing rates declined during the COVID-19 pandemic in 2020, according to a study published in the journal Population Health Management. Harvey W Kaufman, MD, MBA, FCAP, senior medical director, information ventures and office of chief medical officer at Quest Diagnostics conducted the study along with colleagues.

Quest Diagnostics had been preparing for 2020 for two years. As one of the top medical-testing providers in the nation, it first launched its consumer-initiated testing program, QuestDirect, at the end of 2018. Through it, consumers can visit the company's website and order at-home testing kits for 49 different conditions.

Nearly six years after launching a joint venture with IQVIA’s contract research progenitor, Quintiles, Quest Diagnostics is handing over the remainder of its minority share in return for $760 million in cash.

Quest Diagnostics is offering $0 out-of-pocket testing. Drive-thru testing is available Monday through Friday, from 9 a.m. to 4 a.m. Partnering with Walmart locations, appointments can be made through Quest Diagnostics’ online portal.

The COVID-19 pandemic affected diagnostic testing much like it did other parts of the healthcare delivery system — it demanded completely novel approaches at some points, and merely accelerated trends underway at others. In other words, an evolution became a revolution. That revolution, according to Quest Diagnostics Chief Medical Officer Jay Wohlgemuth, MD, can be categorized by just a few words, most notably “convenience.”

Quest Diagnostics recently signed a non-exclusive license agreement with Zora Biosciences Oy, a renowned clinical diagnostics company working to identify robust markers of disease. The agreement is expected to enable Quest Diagnostics in the development of a test service based on Zora's patented ceramide-analysis technology.

With the COVID-19 pandemic accelerating interest in telehealth and consumer-initiated testing, Quest Diagnostics is expanding its existing DTC operation to try to capture $250 million of the emerging market.

Quest Diagnostics' purchase of some lab operations of a St. Louis-based hospital system will bring a positive result for Lenexa. Quest announced this week that it will acquire the outreach laboratory services business of Mercy.

Commercial laboratory Quest Diagnostics Inc. sees a growing direct-to-consumer testing opportunity following the Covid-19 pandemic, as patients seek greater control of their health care and the crisis accelerates a shift to digital technologies.

With the acquisition, Quest will pick up the business from 29 Mercy hospital labs and two independent clinic labs servicing patients and providers throughout Arkansas, Kansas, Missouri, and Oklahoma.

Quest Diagnostics and 98point6 have teamed up to make it easier for patients to connect with a doctor virtually about lab results.

Quest Diagnostics introduced a new blood test Wednesday to aid in determining if an individual has developed immunity to the coronavirus by either having had COVID-19 or being vaccinated for it.

Grail has tapped testing giant Quest Diagnostics to help roll out its upcoming multi-cancer blood test, expected to launch in the coming months.

Low-cost rapid COVID-19 testing is now more accessible across the city, thanks to a new testing program being rolled out by the state. It's part of Gov. Cuomo’s New York Forward Rapid Test Program. It will take place at select CVS, Quest Diagnostics and Clarity MedHealth mobile labs across New York City.

Quest Diagnostics officials announced this week that its turnaround times for COVID-19 testing are faster than at any other time during the pandemic — with the “vast majority” being turned around in one day.

Quest Diagnostics said Tuesday it is now sequencing 2,000 tests a week, doubling the amount of genomic sequencing it started performing last month. The company said it is sequencing the tests for the US Centers for Disease Control and Prevention.

Steve Rusckowski, Quest Diagnostics CEO, joins ‘Closing Bell’ to discuss coronavirus testing, covid variants, and his outlook on the pandemic as coronavirus cases decrease in the U.S.

Quest Diagnostics said Thursday that continued high demand for Covid-19 testing helped drive record revenue and earnings for the company in the fourth quarter and throughout 2020.

In this latest episode of the "MHE Talks: Improving Patient Access" series, Senior Editor of MHE, Peter Wehrwein, speaks with Harvey Kaufman, M.D., FCAP, MBA, senior medical director of medical informatics at Quest Diagnostics. The two discussed a recent Quest Diagnostics Health Trends report examining healthcare disparities.

A new Quest Diagnostics survey found Black and Latino Americans are nearly two times as likely as white Americans to say their access to COVID-19 vaccines - when available - would be worse than other racial or ethnic groups.

The initiative, called Choose Healthy Life, is centered on Black churches in New York, Newark, Detroit, Atlanta and Washington, in partnership with United Way, Quest Diagnostics, local health departments and community-based organizations. It aims to give churches resources, training and support to connect people to services.

Quest Diagnostics said Monday that it has secured a contract from the US Centers for Disease Control and Prevention to provide genomic sequencing of SARS-CoV-2. Financial and other terms of the agreement were not disclosed.

Startling results from a new Health Trends™ survey reveal that women are disproportionately experiencing the physical, financial and mental impact of the pandemic.

Three in four Americans who believed they needed a COVID-19 test report that they either did not get one or delayed getting one, according to the results of a survey released by Quest Diagnostics.

Though COVID-19 testing is widely seen as a way to control the pandemic, most Americans are avoiding or delaying getting tested even when they believe taking a test is warranted.